SUMMARY Diabetic retinopathy (DR) progresses over time at different rates in different individuals, with only a limited number of patients developing significant vision loss owing to the two major vision-threatening complications of DR, clinically significant macular edema and proliferative retinopathy. Good metabolic control is important to prevent and delay disease progression, but whereas some patients develop vision-threatening DR complications and vision loss despite good control, others escape vision loss even with poor metabolic control. Microaneurysm turnover has been validated as a prognostic biomarker of development of clinically significant macular edema. Other good candidates for prognostic biomarkers of DR are subclinical macular edema identified by optical coherence tomography and multifocal electroretinography. Percentage retinal thickness decrease is also a good candidate for a predictive biomarker for visual acuity response to anti-VEGF therapy. Although other candidates for systemic biom...
No takes yet. Share an insight, caveat, or question.
Cunha‐Vaz et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: